Regulatory compliance – Page 56

API change not reported during inspection preparation – how to defend manufacturing readiness

Defending Manufacturing Readiness Amid Unreported API Changes During Inspections The pharmaceutical manufacturing landscape is rigorous and unforgiving, especially when it comes to adherence to GMP compliance. One critical scenario that…

Backdated documentation detected during deviation investigation – evidence pack inspectors expect

“`html Managing Backdated Documentation in Deviation Investigations: A Practical Playbook The detection of backdated documentation during a deviation investigation is a critical concern for pharmaceutical manufacturers. Such findings can lead…

Stability data gaps during WHO PQ assessment – CAPA expectations for PQ approval

Addressing Stability Data Gaps During WHO PQ Assessments for Improved CAPA Outcomes The WHO Prequalification (PQ) process is a critical gateway for pharmaceutical companies looking to supply medicines to low-…

Incomplete contemporaneous recording during inspection review – inspection citation risk and mitigation

Addressing Incomplete Contemporaneous Recording During Inspection Review to Mitigate Citation Risks Incomplete contemporaneous recording can lead to significant citation risks during inspections, jeopardizing compliance status and operational integrity in pharmaceutical…

Deviation history questioned during variation management – PQ assessment risk and mitigation

Managing Deviation History in Variation Assessments for PQ: A Comprehensive Playbook In the highly regulated pharmaceutical manufacturing environment, managing deviation histories during the PQ (Prequalification) variation management assessment is critical.…

CAPA effectiveness doubted during variation management – PQ assessment risk and mitigation

Enhancing CAPA Effectiveness in Variation Management for Pharmaceutical Quality Control In the fast-paced world of pharmaceutical manufacturing, the ability to effectively manage variations while ensuring compliance with Good Manufacturing Practices…

Deviation history questioned during variation management – CAPA expectations for PQ approval

Managing Deviations in Variation Control: A CAPA Playbook for PQ Approval In the pharmaceutical manufacturing landscape, deviating from established norms can raise alarm bells during important qualification processes, such as…

API change not reported during requalification – preventing PQ suspension

Playbook for Managing Unreported API Changes during Requalification to Prevent PQ Suspension In the rapidly evolving pharmaceutical landscape, reporting changes to Active Pharmaceutical Ingredients (API) during requalification is essential to…

PQ dossier deficiency during inspection preparation – CAPA expectations for PQ approval

Addressing PQ Dossier Deficiencies During Inspection Preparation: A CAPA-Focused Playbook The process of achieving WHO Prequalification (PQ) is critical for pharmaceutical manufacturers, especially in the context of fulfilling GMP compliance…

Stability data gaps during WHO PQ assessment – documentation gaps reviewers flag

“`html Addressing Stability Data Gaps in WHO PQ assessment and Documentation Issues During the WHO Prequalification (PQ) assessment process, regulatory reviewers often identify stability data gaps as critical issues that…

Deviation history questioned during inspection preparation – documentation gaps reviewers flag

How to Address Documentation Gaps for Deviation History in Preparation for Inspections In the fast-evolving landscape of pharmaceutical manufacturing and quality, the challenge of managing deviation history effectively is a…

CAPA effectiveness doubted during inspection preparation – preventing PQ suspension

“`html Enhancing CAPA Effectiveness in Preparation for WHO Prequalification Inspections The challenge of ensuring effective Corrective and Preventive Actions (CAPA) becomes significantly critical in the context of WHO Prequalification (PQ)…